168 related articles for article (PubMed ID: 36314605)
1. Dutasteride nanoemulsion preparation to inhibit 5-alpha-hair follicle reductase enzymes in the hair follicle; an ex vivo study.
Memar Bashi Aval M; Hoveizi E; Mombeiny R; Kazemi M; Saeedi S; Tavakol S
IET Nanobiotechnol; 2023 Feb; 17(1):13-21. PubMed ID: 36314605
[TBL] [Abstract][Full Text] [Related]
2. Novel iron oxide nanocarriers loading finasteride or dutasteride: Enhanced skin penetration for topical treatment of alopecia.
Afiune LAF; Ushirobira CY; Barbosa DPP; de Souza PEN; Leles MIG; Cunha-Filho M; Gelfuso GM; Soler MAG; Gratieri T
Int J Pharm; 2020 Sep; 587():119709. PubMed ID: 32739394
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia.
Tsunemi Y; Irisawa R; Yoshiie H; Brotherton B; Ito H; Tsuboi R; Kawashima M; Manyak M;
J Dermatol; 2016 Sep; 43(9):1051-8. PubMed ID: 26893187
[TBL] [Abstract][Full Text] [Related]
4. Dutasteride in Androgenetic Alopecia: An Update.
Arif T; Dorjay K; Adil M; Sami M
Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride nanocapsules for hair follicle targeting: Effect of chitosan-coating and physical stimulus.
Ushirobira CY; Afiune LAF; Pereira MN; Cunha-Filho M; Gelfuso GM; Gratieri T
Int J Biol Macromol; 2020 May; 151():56-61. PubMed ID: 32068053
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia.
Boersma IH; Oranje AP; Grimalt R; Iorizzo M; Piraccini BM; Verdonschot EH
Indian J Dermatol Venereol Leprol; 2014; 80(6):521-5. PubMed ID: 25382509
[TBL] [Abstract][Full Text] [Related]
7. Development and Evaluation of Dutasteride Nanoemulgel for the Topical Delivery against Androgenic Alopecia.
Alam M; Mishra A; Yadav KS; Pradhan D; Kar B; Ghosh G; Rath G; Rai VK
Pharm Nanotechnol; 2024 Jan; ():. PubMed ID: 38173065
[TBL] [Abstract][Full Text] [Related]
8. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
Shanshanwal SJ; Dhurat RS
Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
[TBL] [Abstract][Full Text] [Related]
9. Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia.
Rhie A; Son HY; Kwak SJ; Lee S; Kim DY; Lew BL; Sim WY; Seo JS; Kwon O; Kim JI; Jo SJ
PLoS One; 2019; 14(9):e0222533. PubMed ID: 31525235
[TBL] [Abstract][Full Text] [Related]
10. Mesotherapy with dutasteride for androgenetic alopecia: a concise review of the literature.
Rodríguez-Cuadrado FJ; Pinto-Pulido EL; Fernández-Parrado M
Eur J Dermatol; 2023 Feb; 33(1):72. PubMed ID: 37178048
[No Abstract] [Full Text] [Related]
11. Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients.
Chung HC; Lee S; Lee WS
J Dermatol; 2017 Dec; 44(12):1408-1409. PubMed ID: 27988928
[No Abstract] [Full Text] [Related]
12. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery.
Noor NM; Sheikh K; Somavarapu S; Taylor KMG
Eur J Pharm Biopharm; 2017 Aug; 117():372-384. PubMed ID: 28412472
[TBL] [Abstract][Full Text] [Related]
13. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.
Said MA; Mehta A
Curr Urol Rep; 2018 Jun; 19(8):65. PubMed ID: 29909472
[TBL] [Abstract][Full Text] [Related]
14. Familial frontal fibrosing alopecia treated with dutasteride, minoxidil and artificial hair transplantation.
Cranwell WC; Sinclair R
Australas J Dermatol; 2017 Aug; 58(3):e94-e96. PubMed ID: 27273740
[TBL] [Abstract][Full Text] [Related]
15. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
[TBL] [Abstract][Full Text] [Related]
16. Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors - dutasteride and finasteride - in the presence of testosterone.
Hatanaka T; Lulic Z; Mefo T; Booth C; Harrison E; Ong G
Singapore Med J; 2022 Sep; 63(9):552-558. PubMed ID: 34157805
[No Abstract] [Full Text] [Related]
17. Androgenetic alopecia; drug safety and therapeutic strategies.
Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
[TBL] [Abstract][Full Text] [Related]
18. Physcion, a novel inhibitor of 5α-reductase that promotes hair growth in vitro and in vivo.
Lao Z; Fan Y; Huo Y; Liao F; Zhang R; Zhang B; Kong Z; Long H; Xie J; Sang C; Fu L; Lin J; Wu Y; Yu L; Li G
Arch Dermatol Res; 2022 Jan; 314(1):41-51. PubMed ID: 33635414
[TBL] [Abstract][Full Text] [Related]
19. Gas chromatography/mass spectrometry based hair steroid profiling may reveal pathogenesis in hair follicles of the scalp.
Jung HJ; Kim SJ; Lee WY; Chung BC; Choi MH
Rapid Commun Mass Spectrom; 2011 May; 25(9):1184-92. PubMed ID: 21488116
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
Gupta AK; Charrette A
J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
